Daxor Corporation (DXR)

NASDAQ: DXR · IEX Real-Time Price · USD
13.76
-0.14 (-1.01%)
At close: Aug 5, 2022 4:00 PM
13.90
+0.14 (1.02%)
After-hours: Aug 8, 2022 4:00 PM EDT
-1.01%
Market Cap 55.59M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 4.04M
EPS (ttm) 1.16
PE Ratio 11.86
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 888
Open 14.45
Previous Close 13.90
Day's Range 13.76 - 14.45
52-Week Range 8.82 - 14.45
Beta -0.94
Analysts Buy
Price Target 22.95 (+66.8%)
Earnings Date n/a

About DXR

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 a... [Read more...]

Industry Health Care Equipment & Supplies
Founded 1970
Country United States
Stock Exchange NASDAQ
Ticker Symbol DXR
Full Company Profile

Analyst Forecast

According to 6 analysts, the average rating for DXR stock is "Buy." The 12-month stock price forecast is 22.95, which is an increase of 66.79% from the latest price.

Price Target
$22.95
(66.79% upside)
Analyst Consensus: Buy
Stock Forecasts

News

DAXOR ANNOUNCES COOPERATIVE RESEARCH AND DEVELOPMENT PHASE II AGREEMENT WITH THE UNIFORMED ARMED SERVICES UNIVERSITY ...

New BVA Device Aims to Possess Gold Standard Accuracy and Reproducibility with Increased Safety, Access, Ease of Use, and Frequency of Testing Afforded by a Non-Nuclear Tracer

Daxor's Blood Volume Analyzer (BVA-100®) To Be Used As a Key Metric in Study of “Long Hauler” COVID-19 Patients

Oak Ridge, TN, May 25, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today participation in the National Institutes of Hea...

Daxor Corporation to Present at the H.C. Wainwright & Company Global Investment Conference

NEW YORK, May 12, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today that President and CEO Michael Feldschuh will presen...

Daxor Corporation to Participate in the Maxim Group 2022 Virtual Growth Conference

Oak Ridge, TN, March 23, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces that President and CEO Michael Feldschuh will prese...

Study Demonstrates Importance and Clinical Utility of Daxor's Blood Volume (BVA-100®) Diagnostic in the Assessment of...

Daxor 's BVA-100® Shown to Provide Unique and Actionable Data for Addressing Heart Failure

Daxor Corporation Commences Trading on The NASDAQ Capital Market

Management to Ring the Nasdaq Stock Market Opening Bell on February 4, 2022

Caleb DesRosiers, JD, MPA Appointed to Daxor Corporation Board of Directors

Oak Ridge, TN, Jan. 21, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, announced today that it has appointed Caleb DesRosiers, JD, MPA ...

Daxor Corporation to Commence Trading on The Nasdaq Capital Market On February 2, 2022

Oak Ridge, TN, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces that it will commence trading on The Nasdaq Capi...

Daxor Corporation to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference

Oak Ridge, TN, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces that CEO and President Michael Feldschuh will pr...

DAXOR AWARDED NEW PATENT FOR BLOOD VOLUME GUIDANCE TECHNOLOGY TO IMPROVE TREATMENT AND OUTCOMES

Method Patent Covers Blood Volume Analysis Technology to Evaluate and Guide Treatment Decisions in Multiple Medical Conditions

Daxor Corporation Receives $200K Matching Fund Award from Launch Tennessee

The SBIR/STTR Matching Fund Grant Will Advance the Company's Innovation and Commercialization Efforts, and Job Creation

Daxor Corporation Presents New Data Validating the Benefit of the BVA-100® Blood Test for Heart Failure Patients at K...

Data from Three New Studies and Two Ongoing Trials Presented at the Heart Failure Society of America Annual Scientific Meeting 2021 Data Highlight Importance of Blood Volume Analysis in Providing Approp...

Daxor Corporation to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference

Oak Ridge, TN, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Daxor Corpor a tion (NYSE:DXR), the global leader in blood volume measurement technology, today announces that President and Chief Executive Officer Mic...

Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders

Oak Ridge, TN, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, announces today it issued a corporate update in a Letter to Sha...

Daxor Corporation Reports a 26.5 Percent Rise in Diagnostic Sales Revenue in Form N-CSR Filing for the Six Months End...

Company forecasts further increase in sales driven by new distributor agreements

Daxor's Blood Volume (BVA-100®) Diagnostic Demonstrates Clinical Utility In Critically-Ill COVID-19 Patients In Newly...

Data Led to Multi-Center Study In Progress At Three Leading Hospitals

DAXOR CORPORATION ANNOUNCES NON-GOVERNMENT DISTRIBUTION AGREEMENT WITH CONCORDANCE® HEALTHCARE SOLUTIONS

NEW YORK, July 22, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, announces today that it has signed a non-government distribution ...

American College of Cardiology (ACC) Features Expert Analysis on the Importance of Addressing Anemia With Blood Volum...

Cites Evidence from Studies Utilizing Daxor's BVA-100® Blood Volume Analyzer

Daxor Corporation to Present at the Summer Solstice - Best Ideas from the Buy Side Conference on June 2, 2021

NEW YORK, May 28, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces that Michael Feldschuh, Daxor's President and Chief Ex...

Daxor Corporation Announces 61% Increase in Q1 2021 Sales Revenue and Further Acquisitions of its BVA-100® Blood Volu...

NEW YORK, NY, May 13, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, today announced a Q1 2021 increase in revenue of 61% in its op...

Newly Published Study Demonstrates Clinical Utility of Daxor's Blood Volume (BVA-100®) Diagnostic in the Assessment o...

NEW YORK, April 29, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, today announces new data demonstrating the clinical utility of t...

Daxor to Participate in the Maxim Group 2021 Emerging Growth Virtual Conference

NEW YORK, March 16, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, announces today that President and CEO Michael Feldschuh will presen...

DAXOR CORPORATION ANNOUNCES NOVEL FLUORESCENT TRACER AND PHASE-TWO US AIR FORCE CONTRACT AWARD OF $750,000 FOR POINT-...

BREAKTHROUGH PATENT-PENDING TRACER DEVELOPED FOR BROAD USE

Daxor Corporation Announces $0.48 Per Share NAV Increase and Files Annual Report for Fiscal 2020

Revenues of Operating Division Increase by 50.4%